ALEC Alector, Inc.

Nasdaq alector.com


$ 1.49 $ 0.03 (2.04 %)    

Friday, 24-Oct-2025 18:59:40 EDT
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 1.5
$ 1.46
$ 1.32 x 115
$ 1.53 x 350
$ 1.33 - $ 1.54
$ 0.87 - $ 6.14
6,637,541
na
151.82M
$ 1.58
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-26-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-27-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-03-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-11-2020 06-30-2020 10-Q
22 05-13-2020 03-31-2020 10-Q
23 03-24-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-12-2019 06-30-2019 10-Q
26 05-13-2019 03-31-2019 10-Q
27 03-26-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 clinical-failure-halts-alectors-dementia-program-company-reduces-workforce

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued...

 td-cowen-downgrades-alector-to-hold

TD Cowen analyst Yaron Werber downgrades Alector (NASDAQ:ALEC) from Buy to Hold.

 cantor-fitzgerald-downgrades-alector-to-neutral

Cantor Fitzgerald analyst Pete Stavropoulos downgrades Alector (NASDAQ:ALEC) from Overweight to Neutral.

 hc-wainwright--co-maintains-buy-on-alector-lowers-price-target-to-5

HC Wainwright & Co. analyst Andrew Fein maintains Alector (NASDAQ:ALEC) with a Buy and lowers the price target from $10 ...

 william-blair-downgrades-alector-to-market-perform

William Blair analyst Myles Minter downgrades Alector (NASDAQ:ALEC) from Outperform to Market Perform.

 btig-downgrades-alector-to-neutral

BTIG analyst Thomas Shrader downgrades Alector (NASDAQ:ALEC) from Buy to Neutral.

 alector-says-workforce-reduction-impacts-about-75-employees-restructuring-charges-expected-to-be-about-77m

- SEC Filing

 alector-discontinues-open-label-extension-for-latozinemab-co-to-reduce-workforce-by-about-49

Alector Pipeline OutlookAlector remains focused on advancing a pipeline of programs designed to treat neurodegenerative disease...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION